| Features: |
| Sulindac — Nonsteroidal anti-inflammatory drug (NSAID) and prodrug that is metabolized to the active sulfide metabolite sulindac sulfide. Sulindac inhibits cyclooxygenase activity and prostaglandin synthesis and also exhibits multiple COX-independent effects relevant to cancer biology. Drug class: NSAID / anti-inflammatory drug / repurposed anticancer and chemopreventive agent. Primary mechanism: Sulindac sulfide inhibits COX-1 and COX-2, reducing prostaglandin synthesis. Anticancer effects may also involve COX-independent pathways including cGMP phosphodiesterase inhibition, Wnt/beta-catenin modulation, NF-kB suppression, MAPK/ERK signaling changes, apoptosis induction, and altered RAS-associated signaling. Cancer relevance: Strongest in colorectal adenoma and colorectal cancer prevention research. Sulindac has demonstrated regression and suppression of colorectal adenomas in familial adenomatous polyposis (FAP) and has extensive preclinical anticancer evidence. Its long-term preventive use is limited by NSAID-related gastrointestinal, renal, and cardiovascular toxicity. Typical target/pathway effects: COX-1 ↓; COX-2 ↓; prostaglandin synthesis ↓; PGE2 ↓; NF-kB signaling ↓; MAPK/ERK signaling ↓ in some models; proliferation ↓; apoptosis ↑; colorectal adenoma growth ↓. COX-independent effects should be recorded separately when specifically demonstrated. Alzheimer’s disease relevance: Experimental / repurposing interest. Sulindac sulfide has been reported to modulate gamma-secretase-related amyloid-beta production, including reduction of Aβ42 in experimental systems, and may influence inflammatory signaling through PPARγ/NF-kB-related mechanisms. Clinical efficacy for Alzheimer’s disease has not been established. Important metabolites: Sulindac sulfide is the major pharmacologically active metabolite; sulindac sulfone (exisulind) is an oxidized metabolite with distinct pharmacology. |
| 8654- | MBZ, | SUL, | Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model |
| - | in-vivo, | Colon, | HT-29 | - | in-vitro, | Colon, | SW48 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:493 Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid